{
    "nct_id": "NCT04745234",
    "official_title": "Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)",
    "inclusion_criteria": "* Histologically confirmed diagnosis of MF or SS\n\n  * Stage IB, II-A, II-B, III, or IV;\n* Participants who have failed at least one prior course of systemic therapy (e.g., interferon, bexarotene, photopheresis, anti-neoplastic chemotherapy). Psoralen plus ultraviolet light therapy (PUVA) is not considered a systemic therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current evidence of large cell transformation;\n* Prior treatment with mogamulizumab;\n* History of allogeneic transplant.",
    "miscellaneous_criteria": ""
}